|
|
|
2020
R'000 |
| Impairments and fair value movements comprise the following: |
|
| |
| Impairment of goodwill |
|
– |
213 583 |
| Fair value loss/(gain) on surety receivable |
|
21 116 |
(19 826) |
| Fair value (gain)/loss on financial instruments |
|
(28 911) |
170 476 |
|
|
| (7 795) |
364 233 |
| Bad debts and expected credit loss, arising from the application of IFRS 9, comprise the following: |
|
| |
| Bad debts and expected credit loss on loans |
|
6 181 |
4 652 |
| Expected credit loss on 2DFine and OSI loans* |
|
(67 991) |
51 562 |
| Remeasurement of financial guarantee contracts |
|
(33 455) |
(7 829) |
| Bad debts and expected credit losses on trade receivables, other receivables and advances to customers |
|
83 365 |
67 947 |
|
|
| (11 900) |
116 332 |
| Included in other expenses, impairments and fair value movements, and bad debts and expected credit loss above are the following: |
|
| |
| Impairments, fair value and foreign exchange movements relating to Oxigen |
|
| |
| Expected credit loss on 2DFine loan* |
|
(55 540) |
42 387 |
| Expected credit loss on OSI loan* |
|
(12 451) |
9 175 |
| Foreign exchange loss/(gain) on 2DFine loan |
|
55 811 |
(41 162) |
| Foreign exchange loss/(gain) on OSI loan |
|
12 451 |
(9 175) |
| Fair value loss/(gain) on surety receivable |
|
21 116 |
(19 826) |
| Foreign exchange (gain)/loss and expected credit loss on financial guarantee contracts |
|
(16 605) |
10 166 |
|
|
| 4 782 |
(8 435) |
| Impairments and fair value losses relating to Cell C |
|
| |
| Fair value (gain)/loss on SPV1 and SPV2 |
|
(16 009) |
48 694 |
|
|
| (16 009) |
48 694 |